Biohaven released the results from their RESILIENT SMA clinical trial, and they did not meet the primary endpoint. Biohaven is currently analysing the data further and is engaging in discussion with Health Authorities.
We're excited to announce that SMA News Today has featured our OdySMA real-life stories initiative, as part of their latest publication!
Today, December 5th, we join the global celebration of International Volunteers Day! SMA Europe extends heartfelt gratitude to our dedicated volunteers who generously devote their time and energy to driving positive change in the SMA community worldwide.
Denmark has achieved a major milestone in SMA advocacy!
On 28 August 2024, after years of tireless efforts, the country secured access to SMA treatment for much of the community, including adults.